Individualized Information Sharing Important in All Stages of Cancer Care
the Cancer Therapy Advisor take:
Appropriate, individualized sharing of information for patients with cancer was determined to be important during treatment, at the time of hospital discharge, and in primary care, according to an article published online in the journal European Journal of Cancer Care.
The authors of this study aimed to explore cancer survivors’ experiences regarding information they were given about potential long-term and late effects of pelvic radiotherapy.
Twenty-eight cancer survivors who had received pelvic radiotherapy for a range of cancers (1-11 years prior to the study) were interviewed. Participants from a larger questionnaire survey of patients treated at another hospital were also interviewed.
Results showed the patients acknowledged the potential ability of information to reassure and inform patients, but also identified its ability to produce undesirable effects or raise anxieties about future problems.
Furthermore, the participants identified the importance of the timing, amount of information provided, and context of their situations—value was also placed on information based on personal experience.
Appropriate, individualized sharing of information for patients with cancer was determined to be important during all stages.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Immune Checkpoint Inhibitors for NSCLC: Current and Future Approaches
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- Erdafitinib Granted FDA Breakthrough Therapy Designation for Urothelial Carcinoma
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma
- CLL: Venetoclax Plus Rituximab Improves 2-Year PFS
- Confronting Racial Disparities in Prostate Cancer Survival Outcomes
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma